AbbVie Inc. EBT margin

EBT margin of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBT margin growth rates and interactive chart. The Earnings before tax margin. Calculated as earnings before tax divided by revenue. Measures the profitability of a company after all expenses are paid but before taxes. This is useful to compare various companies in an industry that might have different tax regimes or tax rates.

Highlights and Quick Summary

  • EBT margin for the quarter ending December 30, 2019 was 35.32% (a 49.66% increase compared to previous quarter)
  • Year-over-year quarterly EBT margin increased by 8.68%
  • Annual EBT margin for 2019 was 25.33% (a 59.61% increase from previous year)
  • Annual EBT margin for 2018 was 15.87% (a -42.06% decrease from previous year)
  • Annual EBT margin for 2017 was 27.39% (a -10.93% decrease from previous year)
  • Twelve month EBT margin ending December 30, 2019 was 25.33% (a 179.58% increase compared to previous quarter)
  • Twelve month trailing EBT margin increased by 67.31% year-over-year
Trailing EBT margin for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
25.33% 9.06% 11.46% 15.14%
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBT margin of AbbVie Inc.

Most recent EBT marginof ABBV including historical data for past 10 years.

Interactive Chart of EBT margin of AbbVie Inc.

AbbVie Inc. EBT margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 35.32% 23.6% 9.78% 32.5% 25.33%
2018 -28.57% 33.52% 24.31% 35.25% 15.87%
2017 15.42% 29.95% 33.89% 31.91% 27.39%
2016 29.4% 31.31% 32.49% 29.81% 30.75%
2015 30.06% 27.71% 30.65% 27.7% 29.07%
2014 -19.02% 13.69% 29.09% 28.18% 11.87%
2013 28.15% 27.61% 29.16% 28.62% 28.38%
2012 32.9% 35.58% 31.2% 24.11% 31.15%
2011 57.76% 0.0% 0.0% 22.03% 21.03%
2010 30.92%
2009 41.86%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.